TY - JOUR
T1 - PIK3CA-CDKN2A clonal evolution in metastatic breast cancer and multiple points cell-free DNA analysis
AU - Palmieri, Maria
AU - Baldassarri, Margherita
AU - Fava, Francesca
AU - Fabbiani, Alessandra
AU - Campennì, Giuseppe Maria
AU - Mencarelli, Maria Antonietta
AU - Tita, Rossella
AU - Marsili, Stefania
AU - Renieri, Alessandra
AU - Frullanti, Elisa
PY - 2019/10/28
Y1 - 2019/10/28
N2 - Background: Daily experience tells us that breast cancer can be controlled using standard protocols up to the advent of a relapse. Now new frontiers in precision medicine like liquid biopsy of cell free DNA (cfDNA) give us the possibility to understand cancer evolution and pick up the key mutation on specific cancer driver gene. However, tight schedule of standardized protocol may impair the use of personalized experimental drugs in a timely therapeutic window. Main body: Here, using a combination of deep next generation sequencing and cfDNA liquid biopsy, we demonstrated that it is possible to monitor cancer relapse over time. We showed for the first time the exact correspondence from the increasing clonal expansion and clinical worsening of metastatic breast cancer. Conclusion: Thanks to liquid biopsy may be possible to introduce new experimental drugs in the correct therapeutic window which would lead in the near future to an effective treatment which otherwise remains challenging.
AB - Background: Daily experience tells us that breast cancer can be controlled using standard protocols up to the advent of a relapse. Now new frontiers in precision medicine like liquid biopsy of cell free DNA (cfDNA) give us the possibility to understand cancer evolution and pick up the key mutation on specific cancer driver gene. However, tight schedule of standardized protocol may impair the use of personalized experimental drugs in a timely therapeutic window. Main body: Here, using a combination of deep next generation sequencing and cfDNA liquid biopsy, we demonstrated that it is possible to monitor cancer relapse over time. We showed for the first time the exact correspondence from the increasing clonal expansion and clinical worsening of metastatic breast cancer. Conclusion: Thanks to liquid biopsy may be possible to introduce new experimental drugs in the correct therapeutic window which would lead in the near future to an effective treatment which otherwise remains challenging.
KW - cfDNA
KW - Deep-next generation sequencing
KW - Liquid biopsy
KW - PIK3CA-CDKN2A
KW - Targeted-therapy
UR - http://www.scopus.com/inward/record.url?scp=85074489740&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85074489740&partnerID=8YFLogxK
U2 - 10.1186/s12935-019-0991-y
DO - 10.1186/s12935-019-0991-y
M3 - Review article
AN - SCOPUS:85074489740
VL - 19
JO - Cancer Cell International
JF - Cancer Cell International
SN - 1475-2867
IS - 1
M1 - 274
ER -